Andrzej Kutarski, M.D., PH.D; Barbara Małecka, M.D., PH.D; Agnieszka Kołodzinska, M.D., PH.D; Marcin Grabowski, M.D., PH.D In our subgroup of patients without ...
European Society of Cardiology (ESC) guidance advises that treatment should last for at least six weeks in patients with ...
Currently, echocardiographic contrast agents are indicated for LV opacification and endocardial border definition in patients with technically suboptimal studies. The two FDA approved agents in ...
Holdings announced the completion of the first procedures in FULCRUM-VT U.S. Food and Drug Administration FDA Pivotal ...
Greetings, and welcome to the Pulse Biosciences' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session ...
28don MSN
EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for ...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary ...
Greetings and welcome to the Pulse Biosciences third quarter, 2024 financial results conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback